Welcure Drugs Surges with Rs 300 Cr Export Orders in Q1 FY26

Welcure Drugs & Pharmaceuticals Ltd announced a stellar performance, completing seven export-sourcing orders worth Rs 299.91 crore in the first quarter of FY 2025-26. Operating as a procurement agent, the company earned a fixed 5% commission—approximately Rs 15 crore—on these transactions, reinforcing its fee-based revenue model, according to a regulatory filing.

The orders, executed as part of routine export-sourcing services, involved seven overseas clients, each contributing roughly Rs 42.8 crore. Welcure emphasized its commitment to expanding its export portfolio while maintaining a debt-free capital structure, a strategy that has bolstered investor confidence. Last month, the company secured Rs 85.6 crore in orders from Giant Exim and Ravina International for mycorrhizal inoculant procurement and a Rs 517 crore global sourcing mandate from Thailand’s Fortune SagarImpex.

With its stock hitting the upper circuit and a market cap of Rs 153 crore, Welcure’s focus on high-margin, low-risk deals positions it for sustained growth in the pharmaceutical export sector.

Also Read: Thane Erupts in Marathi Pride Rally Amid Language Row Tensions

Also Read: Telangana’s ‘Rail Roko’ Protest Set for July 17 to Push for 42% OBC Reservation